Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 11:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,224 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: SARS-CoV-2 Clear all
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Children

NCT04816643
View directory record Official record
Conditions
SARS-CoV-2 Infection, COVID-19
Interventions
Biological/Vaccine: BNT162b2 10mcg, BNT162b2 20mcg, BNT162b2 30mcg, Placebo, Biological/Vaccine: BNT162b2 3mcg
Biological · Other
Lead sponsor
BioNTech SE
Industry
Eligibility
6 Months to 15 Years
Enrollment
11,837 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
90
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 67 more
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Jul 21, 2026, 11:10 AM EDT
Completed Phase 2 Interventional Results available

CRISIS2: A Phase 2 Study of the Safety and Antiviral Activity of Brequinar in Non-hospitalized Pts With COVID-19

NCT04575038
View directory record Official record
Conditions
COVID-19 Infection
Interventions
Brequinar, Placebo
Drug
Lead sponsor
Clear Creek Bio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
14
States / cities
Homewood, Alabama • Long Beach, California • Doral, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2022 · Synced Jul 21, 2026, 11:10 AM EDT
Withdrawn Not applicable Interventional

Double-Blind Randomized Placebo-Controlled Trial of a Proprietary Full Hemp Flower Formulation for Long COVID

NCT05467904
View directory record Official record
Conditions
Post-acute COVID-19 Syndrome
Interventions
Xltranplus, Xltran
Other
Lead sponsor
LUCINDA BATEMAN, MD
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Jul 21, 2026, 11:10 AM EDT
Withdrawn Phase 4 Interventional

Effects of DPP4 Inhibition on COVID-19

NCT04341935
View directory record Official record
Conditions
Coronavirus Infection, Type 2 Diabetes
Interventions
Linagliptin, Insulin regimen
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Jul 21, 2026, 11:10 AM EDT
Not listed Phase 2 Interventional

IRAK 4 Inhibitor (PF-06650833) in Hospitalized Patients With COVID-19 Pneumonia and Exuberant Inflammation.

NCT04933799
View directory record Official record
Conditions
COVID-19 Pneumonia
Interventions
PF-06650833, Matching Placebo
Drug
Lead sponsor
Giovanni Franchin, M.D, Ph.D
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jun 21, 2021 · Synced Jul 21, 2026, 11:10 AM EDT
Recruiting Phase 2 Interventional

A Study to Assess Anktiva in Patients With Long Covid-19.

NCT07108036
View directory record Official record
Conditions
Long COVID
Interventions
N-803 (IL-15 Superagonist)
Drug
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Jul 21, 2026, 11:10 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Rural Tailored COVID-19 Communication to Promote SARS-CoV-2 Antibody Testing in Saliva

NCT06085547
View directory record Official record
Conditions
SARS-CoV2 Infection
Interventions
General SARS-CoV-2 Communication, Rural-Targeted SARS-CoV-2 Communication
Behavioral
Lead sponsor
Michigan State University
Other
Eligibility
18 Years and older
Enrollment
264 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Flint, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 16, 2025 · Synced Jul 21, 2026, 11:10 AM EDT
Completed Phase 2 Interventional Results available

Smell in Covid-19 and Efficacy of Nasal Theophylline

NCT04789499
View directory record Official record
Conditions
Covid19, Anosmia, Olfactory Disorder, Covid-19 Pandemic, SARS-CoV-2 Infection, Hyposmia, Ageusia, Hypogeusia
Interventions
Theophylline Powder, Placebo Comparator
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 70 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 23, 2023 · Synced Jul 21, 2026, 11:10 AM EDT
Completed Not applicable Interventional

RECOVER-ENERGIZE Platform Protocol

NCT06404047
View directory record Official record
Conditions
Long COVID, Long Covid19, Long Covid-19
Interventions
Personalized Cardiopulmonary Rehabilitation, Structured Pacing, Education, Usual Care
Behavioral · Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
42
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Jul 21, 2026, 11:10 AM EDT
Active, not recruiting No phase listed Observational

COVID-19 Outcome Prediction Algorithm

NCT05471011
View directory record Official record
Conditions
COVID-19, Post Acute Sequelae of COVID-19, Long COVID, Organ Dysfunction Syndrome, Multiple, Frailty Syndrome
Interventions
Blood and nasal swab sampling
Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
7
States / cities
Los Angeles, California • Sylmar, California • Torrance, California + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Jul 21, 2026, 11:10 AM EDT
Completed Not applicable Interventional

Vagal Approaches on Long COVID-19

NCT07190105
View directory record Official record
Conditions
Long COVID Symptoms
Interventions
Sonocea Sonic Augmentation Technology (SAT), Truvaga Electrical Vagus Nerve Stimulator
Other
Lead sponsor
Leidos Life Sciences
Industry
Eligibility
18 Years and older
Enrollment
546 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Frederick, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Jul 21, 2026, 11:10 AM EDT
Recruiting No phase listed Observational

Natural History of Systemic and Nasal Mucosal Immunity to Influenza and SARS-CoV-2 in Adults After Vaccination

NCT04794829
View directory record Official record
Conditions
Influenza, COVID-19
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 120 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Jul 21, 2026, 11:10 AM EDT
Terminated Phase 3 Interventional Results available

Janssen Ad26.CoV2.S Vaccine Booster in Kidney Transplant Recipients

NCT05220397
View directory record Official record
Conditions
Kidney Transplant Recipient
Interventions
Janssen Ad26.CoV2.S Vaccine, Reduction in Immunosuppression Medication, Maintenance in Immunosuppression Medication
Biological · Other
Lead sponsor
Mark Stegall
Other
Eligibility
18 Years and older
Enrollment
468 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
3
States / cities
Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 14, 2025 · Synced Jul 21, 2026, 11:10 AM EDT
Completed No phase listed Observational

Evaluation of Antibody Tests for COVID-19

NCT04360954
View directory record Official record
Conditions
COVID, Coronavirus
Interventions
Diagnostic test
Diagnostic Test
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
461 participants
Timeline
2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 3, 2024 · Synced Jul 21, 2026, 11:10 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Shifts in the Respiratory Microbiome and Clinical Outcomes of SARS-CoV-2

NCT04815018
View directory record Official record
Conditions
SARS-CoV-2 Infection, Bacterial Respiratory Tract Infection, Viral Respiratory Tract Infection
Interventions
Not listed
Lead sponsor
Pathnostics
Industry
Eligibility
60 Years and older
Enrollment
185 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
4
States / cities
Delaware, Ohio • Granville, Ohio • Westerville, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 29, 2021 · Synced Jul 21, 2026, 11:10 AM EDT
Active, not recruiting Phase 2 Interventional

Low-Dose Radiotherapy For Patients With SARS-COV-2 (COVID-19) Pneumonia

NCT04466683
View directory record Official record
Conditions
Covid-19, Sars-CoV2, Pneumonia
Interventions
Low dose radiation 35 cGy, High dose radiation 100 cGy
Radiation
Lead sponsor
Ohio State University
Other
Eligibility
50 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
6
States / cities
Boca Raton, Florida • Miami, Florida • Maywood, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Jul 21, 2026, 11:10 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Hospitalized Patient With Confirmed COVID-19 Disease

NCT04382924
View directory record Official record
Conditions
COVID
Interventions
NP-120 (Ifenprodil)
Drug
Lead sponsor
Algernon Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
4
States / cities
Miami, Florida • Chicago, Illinois • Saint Joseph, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2021 · Synced Jul 21, 2026, 11:10 AM EDT
Not listed Not applicable Interventional

Vielight RX Plus for the Treatment of COVID-19 Respiratory Symptoms

NCT04418505
View directory record Official record
Conditions
COVID-19
Interventions
Vielight RX Plus
Device
Lead sponsor
Vielight Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
295 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Port Orange, Florida
Source: ClinicalTrials.gov public record
Updated Jun 13, 2021 · Synced Jul 21, 2026, 11:10 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Collection of SARS CoV-2 (COVID-19) Virus Secretions and Serum for Countermeasure Development

NCT04956445
View directory record Official record
Conditions
Covid19
Interventions
Not listed
Lead sponsor
Tulane University
Other
Eligibility
6 Months to 120 Years
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
2
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Jul 21, 2026, 11:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity Trial of an Oral SARS-CoV-2 Vaccine (VXA-CoV2-1) for Prevention of COVID-19 in Healthy Adults and Boost (VXA-CoV2-1.1-S) at 1 Year Post Initial Vaccination in Subset of Subjects

NCT04563702
View directory record Official record
Conditions
Covid19
Interventions
VXA-CoV2-1
Biological
Lead sponsor
Vaxart
Industry
Eligibility
18 Years to 54 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jun 20, 2024 · Synced Jul 21, 2026, 11:10 AM EDT
Completed No phase listed Observational

Project STARFISH - PRJ0002679

NCT05727202
View directory record Official record
Conditions
SARS-CoV-2 Infection, Influenza A, Influenza Type B, RSV Infection
Interventions
The Applied Biosystems™ TaqPath™ COVID-19, Flu A, Flu B, RSV Select Panel
Diagnostic Test
Lead sponsor
Thermo Fisher Scientific, Inc
Industry
Eligibility
Not listed
Enrollment
1,909 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
17
States / cities
San Diego, California • Lake City, Florida • Miami, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2024 · Synced Jul 21, 2026, 11:10 AM EDT
Terminated Phase 2 Interventional

Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS).

NCT04433546
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, Coronavirus, Hypoxic Respiratory Failure, Hypoxemic Respiratory Failure, Respiratory Complication, Respiratory Insufficiency, Cardiac Dysfunction, Pneumonia, Pulmonary Edema, Pulmonary Inflammation, Respiratory Failure, Cytokine Storm, COVID 19, SARS-CoV-2, Cardiac Event, Cardiac Complication, Cardiac Failure, Cardiac Infarct
Interventions
Pemziviptadil (PB1046), Low Dose (10 mg) Control
Drug
Lead sponsor
PhaseBio Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
4
States / cities
Jacksonville, Florida • Sarasota, Florida • Kansas City, Kansas + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2020 · Synced Jul 21, 2026, 11:10 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

SARS-CoV-2 Immune Responses After COVID-19 Therapy and Subsequent Vaccine

NCT04952402
View directory record Official record
Conditions
Covid19, SARS-CoV2 Infection
Interventions
Study-provided Moderna mRNA-1273 COVID-19 vaccine, Community-provided Moderna mRNA-1273 COVID-19 Vaccine, Community-Provided Pfizer-BioNTech BNT162b2 COVID-19 Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
6
States / cities
Los Angeles, California • San Diego, California • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated May 23, 2023 · Synced Jul 21, 2026, 11:10 AM EDT
Not listed No phase listed Observational

Effect of Apollo Wearable on Long COVID-19 Symptoms.

NCT06097442
View directory record Official record
Conditions
Post-acute Sequelae of SARS-COV-2 Infection
Interventions
Not listed
Lead sponsor
The Board of Medicine
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 26, 2023 · Synced Jul 21, 2026, 11:10 AM EDT